Toronto, Ontario--(Newsfile Corp. - May 30, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased to announce that it is hosting an investor lunch presentation on June 15^th at Modus Restaurant, located at 145 King Street West, Toronto, Ontario M5H 1J8 at 12:00 p.m. EDT, limited to 70 attendees.

"Maintaining the philosophy of treating our investors as customers, I cordially invite shareholders and interested parties to our Investor Lunch Presentation to be held on June 15^th, 2023" commented Tony Di Benedetto, Executive Chairman. "We will be showcasing our InsuJet™ device and discussing international sales forecasts as we look to the commercial rollout of InsuJet™ now approved in 42 countries. Having recently completed two private placements totalling gross proceeds of $4,450,000, sales and marketing efforts are now well underway."

Interested parties must RSVP at the information provided below, as space is limited to 70 attendees.

To RSVP, please email Morna Gorman at This email address is being protected from spambots. You need JavaScript enabled to view it..

The lunch will be comprised of a 30-minute corporate presentation, as well as product displays and demonstrations of NuGen's InsuJet™ device, followed by a Q&A period and reception to follow.

Key management and personnel from NuGen that will be in attendance includes:

Tony Di Benedetto, Executive Chairman

Tony Di Benedetto is a Canadian technology entrepreneur with over 30 years of hands-on experience in building, operating, and divesting technology companies. Most recently, Mr. Di Benedetto was the co-founder of Drone Delivery Canada Corp., which he took public and successfully raised over $120M in equity financing, achieving a market capitalization in excess of $550M.

Mr. Di Benedetto has also co-founded several technology companies including Data Centers Canada - a colocation data center facility in Vaughan, Ontario - which he later sold to TeraGo Networks Inc. Other technology enterprises Mr. Di Benedetto developed include system integration/managed services businesses, hosting, and one of southern Ontario's largest fixed wireless broadband networks, all of which he successfully divested. Mr. Di Benedetto holds a degree from York University.

Richard Buzbuzian, President and CEO

Richard Buzbuzian is a capital markets executive with over 25 years of investment experience in Canada and Europe. Most recently, Mr. Buzbuzian was president and a director of Drone Delivery Canada Corp., which he co-founded, took public, and raised over $120M Canadian in equity financings, achieving a market capitalization in excess of $550M. Mr. Buzbuzian holds a degree from the University of Toronto.

Nicky Canton, COO

Nicky Canton has a background in industrial design engineering as well as business administration with more than 13 years of experience in product development, manufacturing, and regulatory compliance of healthcare products, and more particularly, needle-free injection systems. Mr. Canton was involved in the early development of the current InsuJet™ needle-free injector and has been responsible for both development and production scale-up. Besides R&D, his expertise includes risk management, regulatory compliance, supplier management including manufacturing processes, injection moulding, assembly of medical devices, sterile packaging, and sterilization. He has established two manufacturing sites for NuGen's needle-free injectors and manages their day-to-day operations. Mr. Canton has filed and obtained several patents related to technology of needle-free injection systems in China, Europe, and the United States.

Veronique Laberge, CFO

Veronique Laberge is a chartered professional accountant and holder of the title of auditor. With more than 17 years of experience in professional practice, she specializes in certification mandates, general accounting and acts as a consultant for public and private companies.

Karen Dunlap, Director

Karen Dunlap was President/COO, The Americas, UK, Europe and Board Director at Sol-Millennium Medical Group from September 2011 to December 2019, responsible for the acquisition of devices in order to launch into the US and overseeing markets to develop a strategic platform and establish a global sales/marketing team. Ms. Dunlap was Vice President Sales for NMT, partnering with Pharmaceutical Companies on specific medication delivery, and Regional Manager for Medfusion and Medex, focused on the Neonatal and Pediatric markets, where she has extensive experience in accurate medication delivery systems.

Dr. John, Leombruno, Independent Director

Dr. John Leombruno has executive level experience in many areas of the pharmaceutical industry, including market access, medical information, pharmacovigilance, medical affairs, and business development. He co-founded Patient Direct (a patient support and specialty pharmacy provider) and GMD Distribution (a pharmaceutical distribution, patient support and specialty pharmacy services firm), both of which were acquired by McKesson Canada between 2010 and 2017. In 2019, Dr. Leombruno started OkRx, a Canadian Healthcare software company focusing on helping patients, prescribers, insurers, and pharmaceutical companies manage specialty medications. Dr. Leombruno is formally trained as a Pharmacist and has earned an MBA from Queen's University and a Ph.D. in Pharmacoepidemiology from the University of Toronto.

About NuGen Medical Devices

NuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. The company's products, which include the InsuJet™ and PetJet™ needle-free injection systems, are designed to improve the lives of millions of people and animals. NuGen continues to receive approval in numerous countries, including Canada. NuGen's products are designed for use in several important fields including, but not limited to, diabetes, veterinary medicine, and vaccines.

For further information, please visit:

Websites: www.insujet.com and www.nugenmd.com

Instagram: @NuGenMD

Twitter: @NuGenMD

LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:

Tony Di Benedetto
Executive Chairman
(416) 791-9399
This email address is being protected from spambots. You need JavaScript enabled to view it.

Richard Buzbuzian
President & CEO
(647) 501-3290
This email address is being protected from spambots. You need JavaScript enabled to view it.

To arrange a media interview with NuGen, please contact:

Nelson Hudes
Hudes Communications International
(905) 660-9155
This email address is being protected from spambots. You need JavaScript enabled to view it.

Notice Regarding Forward-Looking Information:

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.